Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)

BACKGROUND. GSK3532795 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor that targets HIV-1 Gag, inhibiting the final protease cleavage between capsid protein p24 and spacer protein-1, producing immature, noninfectious virions. METHODS. This was a phase 2a, rand...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Hwang, Carey, Schürmann, Dirk, Sobotha, Christian, Boffito, Marta, Sevinsky, Heather, Ray, Neelanjana, Ravindran, Palanikumar, Xiao, Hong, Keicher, Christian, Hüser, Andreas, Krystal, Mark, Dicker, Ira B., Grasela, Dennis, Lataillade, Max
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Major Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5848258/
https://ncbi.nlm.nih.gov/pubmed/28369211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cix239
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados